Supriya Ghosh (Editor)

18 Methylaminocoronaridine

Updated on
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Covid-19
PubChem CID  44325016
Formula  C22H29N3O2
Molar mass  367.483 g/mol
ChemSpider  24721797
3D model (Jmol)  Interactive image
18-Methylaminocoronaridine httpsuploadwikimediaorgwikipediacommonsthu

(–)-18-Methylaminocoronaridine (18-MAC) is a second generation synthetic derivative of ibogaine developed by the research team led by the pharmacologist Stanley D. Glick from the Albany Medical College and the chemist Martin E. Kuehne from the University of Vermont. In animal studies it has shown around twice the efficacy of the related compound 18-methoxycoronaridine (18-MC) at reducing self-administration of morphine when administered in an equivalent dose, although it is less effective than 18-MC at reducing methamphetamine administration. Similarly to 18-MC itself, 18-MAC acts primarily as a selective α3β4 nicotinic acetylcholine antagonist, and is even more selective than 18-MC with very little activity as an NMDA antagonist and only slight affinity for the delta opioid receptor.

References

18-Methylaminocoronaridine Wikipedia


Similar Topics
Darragh Rabbitte
Jaak Madison
Yang Yu (footballer)
Topics
 
B
i
Link
H2
L